简介内容:CHD1Li is a potent inhibitor of oncogenic CHD1L, acting on the cat-CHD1L recombinant protein (IC50: μM). CHD1Li is an orally active antitumour agent that significantly reduces the tumour volume of CRC xenografts generated from isolated quasi-mesenchymal cells (M phenotype) with enhanced tumourigenic properties. These cells have enhanced tumourigenic properties.